The estimated Net Worth of Fariborz Kamal is at least $68.3 ezer dollars as of 15 December 2020. Fariborz Kamal owns over 4,347 units of 4D Molecular Therapeutics stock worth over $68,335 and over the last 4 years Fariborz sold FDMT stock worth over $0.
Fariborz has made over 1 trades of the 4D Molecular Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Fariborz bought 4,347 units of FDMT stock worth $99,981 on 15 December 2020.
The largest trade Fariborz's ever made was buying 4,347 units of 4D Molecular Therapeutics stock on 15 December 2020 worth over $99,981. On average, Fariborz trades about 621 units every 0 days since 2020. As of 15 December 2020 Fariborz still owns at least 4,347 units of 4D Molecular Therapeutics stock.
You can see the complete history of Fariborz Kamal stock trades at the bottom of the page.
Fariborz's mailing address filed with the SEC is C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE, CA, 94608.
Over the last 4 years, insiders at 4D Molecular Therapeutics have traded over $22,158,915 worth of 4D Molecular Therapeutics stock and bought 2,479,347 units worth $51,074,981 . The most active insiders traders include Global Investors Lp Viking ..., John F Milligan és Global Investors Lp Viking .... On average, 4D Molecular Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of $1,516,666. The most recent stock trade was executed by Scott Bizily on 19 August 2024, trading 500 units of FDMT stock currently worth $3,245.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
4D Molecular Therapeutics executives and other stock owners filed with the SEC include: